SIGA targets 2027 FDA filing: what it means for SIGA stock

Published on 10/21/2026 at 05:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SIGA targets an FDA filing in first half of 2027 for TPOXX. For SIGA stock, Q2 revenue was USD 41 million and results are due November 5, 2026.

Pipeline and reporting milestones

SIGA targeted an FDA submission in the first half of 2027 on October 12, 2026.
Second-quarter revenue reached USD 41 million, while product-related revenue totaled USD 41 million for the first half of 2026.
Third-quarter results are scheduled for November 5, 2026.

SIGA, US8269171067, Illustration mit AI erstellt.

SIGA Technologies (ISIN US8269171067) is targeting an FDA submission for its post-exposure prophylaxis program in the first half of 2027, according to the Benzinga transcript dated October 12, 2026. The program gives investors a longer-term development milestone after a quarter shaped by government and international TPOXX deliveries.

Three dated SIGA milestones

On August 6, 2026, SIGA reported second-quarter revenue of USD 41 million and diluted earnings per share of USD 0.17. On October 2, 2026, MarketBeat reported that Bank of America acquired 427,275 SIGA shares valued at USD 1.56 million during the second quarter. On October 12, 2026, management said it was targeting the first-half 2027 FDA submission.

What does the 2027 filing mean?

The development timetable could broaden TPOXX beyond its existing smallpox use, but the nearer financial picture remains tied to order timing. SIGA generated USD 38 million of product-related revenue in the second quarter, including USD 24 million from intravenous TPOXX deliveries to the U.S. Strategic National Stockpile and USD 13 million from international customers, according to Benzinga. Product-related revenue for the first six months of 2026 reached USD 41 million, showing how concentrated quarterly deliveries can be.

Next reporting date

The next substantiated date is November 5, 2026, when SIGA is scheduled to report its next earnings results, according to TradingView. That release should provide the next hard check on product deliveries, cash generation and progress toward the 2027 regulatory milestone.

Nasdaq valuation context

SIGA was last quoted at USD 3.15 on Nasdaq on October 20, 2026 at 4:00 p.m. ET. Its market capitalization was USD 226.3 million, while the 52-week range stood at USD 2.83 to USD 8.54 on the same market-data snapshot.